These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27922739)

  • 21. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinase Inhibitor Indole Derivatives as Anticancer Agents: A Patent Review.
    Rathi AK; Syed R; Singh V; Shin HS; Patel RV
    Recent Pat Anticancer Drug Discov; 2017; 12(1):55-72. PubMed ID: 27697069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
    Joensuu H
    Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aurora kinases: new targets for cancer therapy.
    Carvajal RD; Tse A; Schwartz GK
    Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benzochalcones bearing pyrazoline moieties show anti-colorectal cancer activities and selective inhibitory effects on aurora kinases.
    Shin SY; Yoon H; Hwang D; Ahn S; Kim DW; Koh D; Lee YH; Lim Y
    Bioorg Med Chem; 2013 Nov; 21(22):7018-24. PubMed ID: 24095020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aurora kinase inhibitors as anti-cancer therapy.
    Lok W; Klein RQ; Saif MW
    Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.
    Ghosh S; Liu XP; Zheng Y; Uckun FM
    Curr Cancer Drug Targets; 2001 Aug; 1(2):129-40. PubMed ID: 12188886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aurora kinases as targets for cancer therapy.
    Mountzios G; Terpos E; Dimopoulos MA
    Cancer Treat Rev; 2008 Apr; 34(2):175-82. PubMed ID: 18023292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aurora kinases and their inhibitors: more than one target and one drug.
    Carpinelli P; Moll J
    Adv Exp Med Biol; 2008; 610():54-73. PubMed ID: 18593015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of tyrosine kinase.
    Klohs WD; Fry DW; Kraker AJ
    Curr Opin Oncol; 1997 Nov; 9(6):562-8. PubMed ID: 9370078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
    Moasser MM; Srethapakdi M; Sachar KS; Kraker AJ; Rosen N
    Cancer Res; 1999 Dec; 59(24):6145-52. PubMed ID: 10626805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aurora kinase A inhibitors: promising agents in antitumoral therapy.
    Malumbres M; Pérez de Castro I
    Expert Opin Ther Targets; 2014 Dec; 18(12):1377-93. PubMed ID: 25200357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.
    Zámečníkova A
    Expert Opin Drug Discov; 2014 Jan; 9(1):77-92. PubMed ID: 24294890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aurora-kinase inhibitors as anticancer agents.
    Keen N; Taylor S
    Nat Rev Cancer; 2004 Dec; 4(12):927-36. PubMed ID: 15573114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and biological evaluation of a novel aurora A kinase inhibitor.
    Sardon T; Cottin T; Xu J; Giannis A; Vernos I
    Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positioning of aminopeptidase inhibitors in next generation cancer therapy.
    Hitzerd SM; Verbrugge SE; Ossenkoppele G; Jansen G; Peters GJ
    Amino Acids; 2014 Apr; 46(4):793-808. PubMed ID: 24385243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.